Publications

After Stock Crash and Staff Cuts, Amarin Wins Bid to Revive Vascepa Patent Lawsuit

Quoted, Fierce Pharma

Chad Landmon, Hatch-Waxman & Biologics Chair, discusses his thoughts on the Amarin-Hikma case.